US20060182732A1 - Composition for mitigating a pernicious thrombotic event - Google Patents

Composition for mitigating a pernicious thrombotic event Download PDF

Info

Publication number
US20060182732A1
US20060182732A1 US11/390,816 US39081606A US2006182732A1 US 20060182732 A1 US20060182732 A1 US 20060182732A1 US 39081606 A US39081606 A US 39081606A US 2006182732 A1 US2006182732 A1 US 2006182732A1
Authority
US
United States
Prior art keywords
composition
person
magnesium
aspirin
blood vessel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/390,816
Inventor
Arnold Nerenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US11/390,816 priority Critical patent/US20060182732A1/en
Publication of US20060182732A1 publication Critical patent/US20060182732A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)

Definitions

  • the present invention relates to a composition for mitigating adverse effects of an imminent or actually-occurring pernicious thrombotic event, such as a heart attack or stroke, in a person.
  • An individual having a heart attack or experiencing symptoms indicating that a heart attack is imminent or probable needs to have medical intervention by medical professionals as soon as possible. Accordingly, there is a need to mitigate the damage that could potentially be done to the individual's coronary system prior to said medical intervention.
  • the present invention provides a composition, comprising: aspirin, magnesium, and nattokinase, and either niacin or nitroglycerine, said composition having a structural form that is suitable for being introduced into a body of a person.
  • the present invention advantageously provides a composition for mitigating adverse effects of an imminent or actually-occurring pernicious thrombotic event, such as a heart attack or stroke, in a person.
  • FIGS. 1-4 depict structural forms of a composition, in accordance with embodiments of the present invention.
  • the present invention provides a therapeutic composition suitable for being introduced into the body (e.g., by means of a body cavity) of a person.
  • This composition is adapted to provide therapeutic benefits to the person during the critical period prior to the arrival or availability of said medical intervention.
  • the therapeutic benefits mitigate the damage that could potentially be done to the individual's coronary system prior to said medical intervention
  • the composition of the present invention includes aspirin, magnesium, and nattokinase, and niacin or nitroglycerine.
  • the composition may include one or more additional ingredients as will be discussed infra.
  • the composition is adapted to be introduced into the body (e.g., body cavity) of the person for mitigating adverse effects of an imminent or actually-occurring heart attack or stroke in the person.
  • the composition has a structural form being suitable for introduction of the composition into the body a person such as, inter alia, one of the structural forms of FIGS. 1-4 or related structural forms as described infra, which depict structural forms of the composition of the present invention in accordance with embodiments thereof.
  • FIG. 1 depicts chewable form 10 , such as a wafer or a chewable pill.
  • the chewable form 10 may have any geometric shape, (e.g., circular, elliptical, rectangular square, triangular, etc.).
  • the size of the chewable form 10 is of a size sufficient to contain all ingredients of the composition in the amounts desired.
  • the chewable form 10 may be, inter alia, circular with a diameter of 11 ⁇ 2 inches and a thickness of 1 ⁇ 2 inch.
  • the chewable form 10 is adapted to be chewed by the person for quick ingestion in the event an imminent or actually-occurring heart attack in a person.
  • the structural form of the present invention may comprise a dissolvable form such as a dissolvable wafer or dissolvable pill, which may be constituted structurally similar to the chewable form 10 shown in FIG. 1 .
  • the dissolvable form may dissolve in the mouth of the person when held under the person's tongue, for quick absorption into the bloodstream of the person in the event an imminent or actually-occurring heart attack in the person.
  • FIG. 2 depicts the liquid form 20 contained in a vial or equivalent container 21 having a top 22 .
  • the top 22 may be, inter alia, a screwable top, a puncturable top, etc.
  • the liquid form 20 is adapted to be swallowed by the person for quick ingestion in the event an imminent or actually-occurring heart attack in a person.
  • the liquid form 20 may alternatively be adapted to be introduced into the body of the person by injection through use of a needle or syringe (at any suitable point of injection on the person's body).
  • the structural form of the present invention may comprise an alternative dissolvable form such as a liquid, which may be constituted structurally similar to the liquid form 20 form shown in FIG. 1 .
  • the dissolvable form may dissolve in the mouth of the person when held under the person's tongue, for quick absorption into the bloodstream of the person in the event an imminent or actually-occurring heart attack in the person.
  • FIG. 3 depicts the spray form 30 contained in a spray bottle or equivalent container 31 having a cover 32 .
  • the cover 32 may be, inter alia, a screwable cover.
  • the spray form 30 may be any type of spray (e.g., aerosol spray in a pressurized container 31 ) as is known in the art.
  • the spray form 30 is adapted to be sprayed into the nasal cavity of the person for quick absorption into the bloodstream of the person in the event an imminent or actually-occurring heart attack in the person.
  • FIG. 4 depicts a suppository form 40 for insertion into the anal cavity of the person for quick absorption into the bloodstream of the person in the event an imminent or actually-occurring heart attack in the person.
  • the ingredients of the composition may be distributed homogeneously or inhomogeneously within the composition.
  • the composition of the present invention comprises four basic ingredients for providing a four-weapon simultaneous assault on the imminent or actually-occurring heart attack experienced by the person, inasmuch as the composition provides a blood thinner (aspirin), a blood clot buster (nattokinase), a means for preventing or reducing damage to the heart (magnesium), and a blood vessel dilator (niacin or nitroglycerine).
  • the different therapeutic roles played by each of the four basic ingredients composition is analogous to a military force simultaneously attacking the enemy in all four directions: north, south, east, and west.
  • the different therapeutic roles played by each of the four basic ingredients composition is analogous to using the four different branches of the armed services (i.e., army, navy, air force, marines) to attack the enemy.
  • aspirin helps to prevent the formation of blood clots.
  • nattokinase attacks fibrin clumps that clot blood vessels.
  • Nattokinase is an enzyme produced by a fermentation process in which the bacteria bacillus natto is added to boiled soybeans. If the person has a deficiency of magnesium, the person is likely to suffer more heart damage during a heart attack than does one not having a magnesium deficiency.
  • niacin or nitroglycerine improve blood circulation, thereby improving the transport of oxygen to the heart.
  • the composition of the present invention may additionally comprise one or more of the following ingredients: L-carnitine, alpha lipoic acid, L-arginine, and coenzyme Q10.
  • L-carnitine e.g., proprionyl L-carnitine
  • Alpha lipoic acid is a fat and water soluble antioxidant that protects tissues from damage associated with low oxygen supply during a heart attack.
  • L-arginine increases local production of nitric oxide, which dilates the smooth muscle found in the linings of blood vessels, thereby leading to a lowering of blood pressure.
  • L-arginine also inhibits aggregation of platelets wherein said platelets promote blood clotting.
  • Coenzyme Q10 increases blood circulation and enhances oxygen levels in the heart muscle.
  • the ingredients comprised by the composition of the present invention may each have a therapeutically effective amount for mitigating adverse effects of an imminent or actually-occurring heart attack in the person.
  • the therapeutically effective amount may be different for different persons.
  • the ingredients comprised by the composition of the present invention may exist, inter alia, in the amount shown in Table 1.
  • TABLE 1 Ingredient Amount Aspirin 650 to 975 mg Magnesium 5000 to 15000 mg Nattokinase 150 to 3000 mg Niacin 500 to 3000 mg Nitroglycerine 0.4 to 2.5 mg L-carnitine 2000 to 9000 mg Alpha lipoic acid 200 to 10000 mg L-arginine 2000 to 12000 mg Coenzyme Q10 300 to 6000 mg
  • ingredients of the composition may be packaged with any base ingredient (e.g., soybean oil, lecithin, etc.) known to a person of ordinary skill in the art as being useful and practical for packaging analogous compositions.
  • any base ingredient e.g., soybean oil, lecithin, etc.
  • composition of the present invention may be modified by adding Vitamin C, zinc, and Vitamin E in therapeutic amounts so as to mitigate adverse effects resulting from heart surgery following a heart attack or otherwise conducted in the absence of a heart attack.
  • Vitamin C, zinc, and Vitamin E may exist in the composition in the following amounts: Vitamin C (1000 to 10000 mg); zinc (90 to 300 mg); and Vitamin E (2000 to 10000 International Units).
  • composition of the present invention is similarly useful for mitigating adverse effects of an imminent or actually-occurring stroke in the person.
  • the composition of the present invention is useful for mitigating adverse effects of an imminent or actually-occurring pernicious thrombotic event in the person. Examples of pernicious thrombotic event include heart attack, stroke, etc.
  • composition of the present invention may also be used to prevent a thrombotic event that has a heightened probability of occurring in the person due to the person anticipating being subjected to a high level of physical or emotional stress; e.g., lifting weights in preparation for (or during) a weight-lifting contest, engaging in battle during a military encounter, being a victim during an airplane hijacking, etc.

Abstract

A composition. The composition comprises aspirin, magnesium, and nattokinase, and either niacin or nitroglycerine. The composition has a structural form of: a chewable form, a dissolvable form, a liquid form, a spray form, or a suppository form. The structural form is suitable for being introduced into the body of a person, such as by means of a body cavity of the person. The composition may be used for mitigating adverse effects of an imminent or actually-occurring pernicious thrombotic event, such as a heart attack or stroke, in the person.

Description

  • This application is a divisional of Ser. No. 10/625,305; filed on Jul. 23, 2003.
    • BACKGROUND OF THE INVENTION
  • 1. Technical Field
  • The present invention relates to a composition for mitigating adverse effects of an imminent or actually-occurring pernicious thrombotic event, such as a heart attack or stroke, in a person.
  • 2. Related Art
  • An individual having a heart attack or experiencing symptoms indicating that a heart attack is imminent or probable needs to have medical intervention by medical professionals as soon as possible. Accordingly, there is a need to mitigate the damage that could potentially be done to the individual's coronary system prior to said medical intervention.
    • SUMMARY OF THE INVENTION
  • The present invention provides a composition, comprising: aspirin, magnesium, and nattokinase, and either niacin or nitroglycerine, said composition having a structural form that is suitable for being introduced into a body of a person.
  • The present invention advantageously provides a composition for mitigating adverse effects of an imminent or actually-occurring pernicious thrombotic event, such as a heart attack or stroke, in a person.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIGS. 1-4 depict structural forms of a composition, in accordance with embodiments of the present invention.
    • DETAILED DESCRIPTION OF THE INVENTION
  • If a person experiences symptoms of an imminent or actually-occurring heart attack, the person needs medical intervention by medical professionals as soon as possible. Accordingly, the present invention provides a therapeutic composition suitable for being introduced into the body (e.g., by means of a body cavity) of a person. This composition is adapted to provide therapeutic benefits to the person during the critical period prior to the arrival or availability of said medical intervention. The therapeutic benefits mitigate the damage that could potentially be done to the individual's coronary system prior to said medical intervention
  • The composition of the present invention includes aspirin, magnesium, and nattokinase, and niacin or nitroglycerine. The composition may include one or more additional ingredients as will be discussed infra. The composition is adapted to be introduced into the body (e.g., body cavity) of the person for mitigating adverse effects of an imminent or actually-occurring heart attack or stroke in the person. Thus, the composition has a structural form being suitable for introduction of the composition into the body a person such as, inter alia, one of the structural forms of FIGS. 1-4 or related structural forms as described infra, which depict structural forms of the composition of the present invention in accordance with embodiments thereof.
  • FIG. 1 depicts chewable form 10, such as a wafer or a chewable pill. Although FIG. 1 shows the chewable form 10 as being round, the chewable form may have any geometric shape, (e.g., circular, elliptical, rectangular square, triangular, etc.). The size of the chewable form 10 is of a size sufficient to contain all ingredients of the composition in the amounts desired. For example, the chewable form 10 may be, inter alia, circular with a diameter of 1½ inches and a thickness of ½ inch. The chewable form 10 is adapted to be chewed by the person for quick ingestion in the event an imminent or actually-occurring heart attack in a person.
  • The structural form of the present invention may comprise a dissolvable form such as a dissolvable wafer or dissolvable pill, which may be constituted structurally similar to the chewable form 10 shown in FIG. 1. The dissolvable form may dissolve in the mouth of the person when held under the person's tongue, for quick absorption into the bloodstream of the person in the event an imminent or actually-occurring heart attack in the person.
  • FIG. 2 depicts the liquid form 20 contained in a vial or equivalent container 21 having a top 22. The top 22 may be, inter alia, a screwable top, a puncturable top, etc. The liquid form 20 is adapted to be swallowed by the person for quick ingestion in the event an imminent or actually-occurring heart attack in a person. The liquid form 20 may alternatively be adapted to be introduced into the body of the person by injection through use of a needle or syringe (at any suitable point of injection on the person's body).
  • The structural form of the present invention may comprise an alternative dissolvable form such as a liquid, which may be constituted structurally similar to the liquid form 20 form shown in FIG. 1. The dissolvable form may dissolve in the mouth of the person when held under the person's tongue, for quick absorption into the bloodstream of the person in the event an imminent or actually-occurring heart attack in the person.
  • FIG. 3 depicts the spray form 30 contained in a spray bottle or equivalent container 31 having a cover 32. The cover 32 may be, inter alia, a screwable cover. The spray form 30 may be any type of spray (e.g., aerosol spray in a pressurized container 31) as is known in the art. The spray form 30 is adapted to be sprayed into the nasal cavity of the person for quick absorption into the bloodstream of the person in the event an imminent or actually-occurring heart attack in the person.
  • FIG. 4 depicts a suppository form 40 for insertion into the anal cavity of the person for quick absorption into the bloodstream of the person in the event an imminent or actually-occurring heart attack in the person.
  • Irrespective of the structural form of the composition, the ingredients of the composition may be distributed homogeneously or inhomogeneously within the composition.
  • The composition of the present invention comprises four basic ingredients for providing a four-weapon simultaneous assault on the imminent or actually-occurring heart attack experienced by the person, inasmuch as the composition provides a blood thinner (aspirin), a blood clot buster (nattokinase), a means for preventing or reducing damage to the heart (magnesium), and a blood vessel dilator (niacin or nitroglycerine). Thus, the different therapeutic roles played by each of the four basic ingredients composition is analogous to a military force simultaneously attacking the enemy in all four directions: north, south, east, and west. As another military analogy, the different therapeutic roles played by each of the four basic ingredients composition is analogous to using the four different branches of the armed services (i.e., army, navy, air force, marines) to attack the enemy.
  • As a blood thinner, aspirin helps to prevent the formation of blood clots. As a clot buster, nattokinase attacks fibrin clumps that clot blood vessels. Nattokinase is an enzyme produced by a fermentation process in which the bacteria bacillus natto is added to boiled soybeans. If the person has a deficiency of magnesium, the person is likely to suffer more heart damage during a heart attack than does one not having a magnesium deficiency. As a blood vessel dilator, niacin or nitroglycerine improve blood circulation, thereby improving the transport of oxygen to the heart.
  • The composition of the present invention may additionally comprise one or more of the following ingredients: L-carnitine, alpha lipoic acid, L-arginine, and coenzyme Q10. L-carnitine (e.g., proprionyl L-carnitine) helps to increase blood flow to the heart and to reduce or prevent heart enlargement. Alpha lipoic acid is a fat and water soluble antioxidant that protects tissues from damage associated with low oxygen supply during a heart attack. L-arginine increases local production of nitric oxide, which dilates the smooth muscle found in the linings of blood vessels, thereby leading to a lowering of blood pressure. L-arginine also inhibits aggregation of platelets wherein said platelets promote blood clotting. Coenzyme Q10 increases blood circulation and enhances oxygen levels in the heart muscle.
  • The ingredients comprised by the composition of the present invention may each have a therapeutically effective amount for mitigating adverse effects of an imminent or actually-occurring heart attack in the person. The therapeutically effective amount may be different for different persons. Accordingly, the ingredients comprised by the composition of the present invention may exist, inter alia, in the amount shown in Table 1.
    TABLE 1
    Ingredient Amount
    Aspirin 650 to 975 mg 
    Magnesium 5000 to 15000 mg
    Nattokinase 150 to 3000 mg
    Niacin 500 to 3000 mg
    Nitroglycerine 0.4 to 2.5 mg 
    L-carnitine 2000 to 9000 mg 
    Alpha lipoic acid  200 to 10000 mg
    L-arginine 2000 to 12000 mg
    Coenzyme Q10 300 to 6000 mg
  • The ingredients of the composition may be packaged with any base ingredient (e.g., soybean oil, lecithin, etc.) known to a person of ordinary skill in the art as being useful and practical for packaging analogous compositions.
  • While the preceding discussion focused on a composition that mitigates adverse effects of an imminent or actually-occurring heart attack in a person, the composition of the present invention may be modified by adding Vitamin C, zinc, and Vitamin E in therapeutic amounts so as to mitigate adverse effects resulting from heart surgery following a heart attack or otherwise conducted in the absence of a heart attack. The Vitamin C, zinc, and Vitamin E may exist in the composition in the following amounts: Vitamin C (1000 to 10000 mg); zinc (90 to 300 mg); and Vitamin E (2000 to 10000 International Units).
  • It is noted that while a heart attack may be accompanied by blood clotting in a coronary artery so as to impede or block blood flow to the heart, a stroke may analogously be accompanied by blood clotting in a blood vessel leading to the brain so as to impede or block blood flow to the brain. Therefore, while the preceding discussion related to the beneficial effect of the ingredients of the composition of the present invention for mitigating adverse effects of an imminent or actually-occurring heart attack in a person, the composition of the present invention is similarly useful for mitigating adverse effects of an imminent or actually-occurring stroke in the person. More generally, the composition of the present invention is useful for mitigating adverse effects of an imminent or actually-occurring pernicious thrombotic event in the person. Examples of pernicious thrombotic event include heart attack, stroke, etc.
  • While the preceding discussion focused on a composition that mitigates adverse effects of an imminent or actually-occurring thrombotic event in a person, the composition of the present invention may also be used to prevent a thrombotic event that has a heightened probability of occurring in the person due to the person anticipating being subjected to a high level of physical or emotional stress; e.g., lifting weights in preparation for (or during) a weight-lifting contest, engaging in battle during a military encounter, being a victim during an airplane hijacking, etc.
  • While embodiments of the present invention have been described herein for purposes of illustration, many modifications and changes will become apparent to those skilled in the art. Accordingly, the appended claims are intended to encompass all such modifications and changes as fall within the true spirit and scope of this invention.

Claims (38)

1. A composition, comprising nattokinase and at least one of aspirin, magnesium, and a blood vessel dilator, said blood vessel dilator being either niacin or nitroglycerine, said composition having a structural form that is suitable for being introduced into a body of a person.
2. The composition of claim 1, wherein the nattokinase and the at least one of aspirin, magnesium, and the blood vessel dilator each have a therapeutically effective amount for mitigating adverse effects of an imminent or actually-occurring pernicious thrombotic event in the person.
3. The composition of claim 2, wherein the pernicious thrombotic event in the person is a heart attack or stroke in the person.
4. The composition of claim 1, wherein the nattokinase has an amount in a range of 150 to 3000 mg.
5. The composition of claim 1, wherein the composition comprises aspirin.
6. The composition of claim 1, wherein the composition comprises magnesium.
7. The composition of claim 1, wherein the composition comprises niacin.
8. The composition of claim 1, wherein the composition comprises nitroglycerine.
9. The composition of claim 1, wherein the composition comprises at least two of aspirin, magnesium, and the blood vessel dilator.
10. The composition of claim 11, wherein the composition comprises aspirin and magnesium.
11. The composition of claim 11, wherein the composition comprises aspirin and the blood vessel dilator.
12. The composition of claim 11, wherein the composition comprises magnesium and the blood vessel dilator.
13. The composition of claim 1, wherein the composition further comprises L-carnitine.
14. The composition of claim 1, wherein the composition further comprises alpha lipoic acid.
15. The composition of claim 1, wherein the composition further comprises L-arginine.
16. The composition of claim 1, wherein the composition further comprises coenzyme Q10.
17. A method, comprising introducing a composition into a person, wherein the composition comprises nattokinase and at least one of aspirin, magnesium, and a blood vessel dilator, wherein the blood vessel dilator is either niacin or nitroglycerine, and wherein the nattokinase and the at least one of aspirin, magnesium, and the blood vessel dilator each have a therapeutically effective amount for mitigating adverse effects of an imminent or actually-occurring-pernicious thrombotic event in the person.
18. The method of claim 17, wherein the pernicious thrombotic event in the person is a heart attack or stroke in the person.
19. The method of claim 17, wherein the nattokinase has an amount in a range of 150 to 3000 mg.
20. The method of claim 17, wherein the composition comprises aspirin.
21. The method of claim 17, wherein the composition comprises magnesium.
22. The method of claim 17, wherein the composition comprises niacin.
23. The method of claim 18, wherein the composition comprises nitroglycerine.
24. The method of claim 17, wherein the composition comprises at least two of aspirin, magnesium, and the blood vessel dilator.
25. The method of claim 24, wherein the composition comprises aspirin and magnesium.
26. The method of claim 24, wherein the composition comprises aspirin and the blood vessel dilator.
27. The method of claim 24, wherein the composition comprises magnesium and the blood vessel dilator.
28. The method of claim 17, wherein the composition further comprises L-carnitine.
29. The method of claim 17, wherein the composition further comprises alpha lipoic acid.
30. The method of claim 17, wherein the composition further comprises L-arginine.
31. The method of claim 17, wherein the composition further comprises coenzyme Q10.
32. A method, comprising introducing a composition into a person, wherein the composition comprises aspirin, magnesium, nattokinase, and a blood vessel dilator, wherein the blood vessel dilator is either niacin or nitroglycerine, and wherein the aspirin, magnesium, nattokinase, and the blood vessel dilator each have a therapeutically effective amount for mitigating adverse effects of an imminent or actually-occurring pernicious thrombotic event in the person.
33. The method of claim 32, wherein the pernicious thrombotic event in the person is a heart attack or stroke in the person.
34. The method of claim 32, wherein the nattokinase has an amount in a range of 150 to 3000 mg.
35. The method of claim 34, wherein the composition further comprises L-carnitine.
36. The method of claim 34, wherein the composition further comprises alpha lipoic acid.
37. The method of claim 34, wherein the composition further comprises L-arginine.
38. The method of claim 34, wherein the composition further comprises coenzyme Q10.
US11/390,816 2003-07-23 2006-03-28 Composition for mitigating a pernicious thrombotic event Abandoned US20060182732A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/390,816 US20060182732A1 (en) 2003-07-23 2006-03-28 Composition for mitigating a pernicious thrombotic event

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/625,305 US7041286B2 (en) 2003-07-23 2003-07-23 Composition for mitigating a pernicious thrombotic event
US11/390,816 US20060182732A1 (en) 2003-07-23 2006-03-28 Composition for mitigating a pernicious thrombotic event

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/625,305 Division US7041286B2 (en) 2003-07-23 2003-07-23 Composition for mitigating a pernicious thrombotic event

Publications (1)

Publication Number Publication Date
US20060182732A1 true US20060182732A1 (en) 2006-08-17

Family

ID=34080183

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/625,305 Expired - Lifetime US7041286B2 (en) 2003-07-23 2003-07-23 Composition for mitigating a pernicious thrombotic event
US11/390,816 Abandoned US20060182732A1 (en) 2003-07-23 2006-03-28 Composition for mitigating a pernicious thrombotic event

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/625,305 Expired - Lifetime US7041286B2 (en) 2003-07-23 2003-07-23 Composition for mitigating a pernicious thrombotic event

Country Status (1)

Country Link
US (2) US7041286B2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
US10195147B1 (en) 2017-09-22 2019-02-05 Otitopic Inc. Dry powder compositions with magnesium stearate

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654209A (en) * 1979-11-06 1987-03-31 Euroceltique, S.A. Preparation for percutaneous administration
US5006516A (en) * 1988-05-02 1991-04-09 Verla-Pharm Arzneimittelfabrik Apotheker H.J.V. Ehrlich Gmbh & Co. Kg. Method for the prophylaxis of cardiac infarctions and the prevention of reinfarctions
US5776498A (en) * 1995-11-06 1998-07-07 Nutrition 21 Magnesium taurate as an adjuvant to rapid thrombolytic therapy
US5948443A (en) * 1996-02-23 1999-09-07 Medical Doctor's Research Institute, Inc. Acetylsalicylic acid and micronutrient supplementation for nutritional losses and coronary heart disease
US5962413A (en) * 1993-07-16 1999-10-05 Schering Aktiengesellschaft Treatment of uterine contractility disorders with a nitric oxide synthase substrate and/or donor, or a nitric oxide inhibitor
US6015577A (en) * 1986-08-13 2000-01-18 Dr. Karl Thomae GmbH Pharmaceutical compositions containing dipyridamole or mopidamol and acetylsalicylic acid or the physiologically acceptable salts thereof, processes for preparing them and their use in treating clot formation
US6048846A (en) * 1998-02-26 2000-04-11 Cochran; Timothy M. Compositions used in human treatment
US6203819B1 (en) * 1997-03-07 2001-03-20 Akesis Pharmaceuticals, Inc. Dietary supplement and method of treatment for diabetic control
US6245811B1 (en) * 1995-05-01 2001-06-12 Scotia Holdings Plc Fatty acid esters as bioactive compounds
US6261250B1 (en) * 1998-08-20 2001-07-17 Rle Corporation Method and apparatus for enhancing cardiovascular activity and health through rhythmic limb elevation
US6369073B1 (en) * 1998-05-15 2002-04-09 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase
US6391895B1 (en) * 1997-12-23 2002-05-21 Amersham Health As Nitric oxide releasing chelating agents and their therapeutic use
US6432986B2 (en) * 1997-07-21 2002-08-13 Bruce H. Levin Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
US20020146786A1 (en) * 2000-04-21 2002-10-10 Shinsaku Takaoka Bacillus natto culture extract
US6669971B1 (en) * 1999-10-28 2003-12-30 Ooyama Tofu Co., Ltd Barley and yam Natto

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235311B1 (en) 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
US20020034555A1 (en) 2000-02-23 2002-03-21 Daniel Gelber Composition and method for treating the effects of diseases and maladies
US20020025917A1 (en) 2000-08-28 2002-02-28 Edward Pappalardo Compartmentalized device to enable a process of liquefying and administering aspirin as a first aid to heart attack victims

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654209A (en) * 1979-11-06 1987-03-31 Euroceltique, S.A. Preparation for percutaneous administration
US6015577A (en) * 1986-08-13 2000-01-18 Dr. Karl Thomae GmbH Pharmaceutical compositions containing dipyridamole or mopidamol and acetylsalicylic acid or the physiologically acceptable salts thereof, processes for preparing them and their use in treating clot formation
US5006516A (en) * 1988-05-02 1991-04-09 Verla-Pharm Arzneimittelfabrik Apotheker H.J.V. Ehrlich Gmbh & Co. Kg. Method for the prophylaxis of cardiac infarctions and the prevention of reinfarctions
US5962413A (en) * 1993-07-16 1999-10-05 Schering Aktiengesellschaft Treatment of uterine contractility disorders with a nitric oxide synthase substrate and/or donor, or a nitric oxide inhibitor
US6245811B1 (en) * 1995-05-01 2001-06-12 Scotia Holdings Plc Fatty acid esters as bioactive compounds
US5776498A (en) * 1995-11-06 1998-07-07 Nutrition 21 Magnesium taurate as an adjuvant to rapid thrombolytic therapy
US5948443A (en) * 1996-02-23 1999-09-07 Medical Doctor's Research Institute, Inc. Acetylsalicylic acid and micronutrient supplementation for nutritional losses and coronary heart disease
US6203819B1 (en) * 1997-03-07 2001-03-20 Akesis Pharmaceuticals, Inc. Dietary supplement and method of treatment for diabetic control
US6432986B2 (en) * 1997-07-21 2002-08-13 Bruce H. Levin Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
US6391895B1 (en) * 1997-12-23 2002-05-21 Amersham Health As Nitric oxide releasing chelating agents and their therapeutic use
US6048846A (en) * 1998-02-26 2000-04-11 Cochran; Timothy M. Compositions used in human treatment
US6369073B1 (en) * 1998-05-15 2002-04-09 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase
US6261250B1 (en) * 1998-08-20 2001-07-17 Rle Corporation Method and apparatus for enhancing cardiovascular activity and health through rhythmic limb elevation
US6669971B1 (en) * 1999-10-28 2003-12-30 Ooyama Tofu Co., Ltd Barley and yam Natto
US20020146786A1 (en) * 2000-04-21 2002-10-10 Shinsaku Takaoka Bacillus natto culture extract

Also Published As

Publication number Publication date
US7041286B2 (en) 2006-05-09
US20050019319A1 (en) 2005-01-27

Similar Documents

Publication Publication Date Title
Ramirez-R Pulmonary aspergilloma: endobronchial treatment
US20230233599A1 (en) Novel Dietary Supplements
Swain et al. Non-sinonasal isolated facio-orbital mucormycosis–A case report
CN112641771A (en) Composition for treating autodigestion
US20060182732A1 (en) Composition for mitigating a pernicious thrombotic event
Lewis et al. A controlled clinical trial of ascorbic acid for the common cold
Edwards et al. A study of leukocytosis in exercise
US10653737B1 (en) Synergistic nutritional compositions for pain management
CN103054855B (en) Composition and preparation method and application thereof
Howard et al. Intraocular tissue plasminogen activator in a rabbit model of traumatic hyphema
US10183068B2 (en) Vaccination compositions, methods of making, and methods of use
Chen et al. Effects of mesenchymal stem cells on postresuscitation renal and intestinal injuries in a porcine cardiac arrest model
Leonardi et al. Evaluation of cholinesterase-restoring agents in the treatment of tetanus in man
EP1539213B1 (en) Cardioprotective therapies based on enzymatic elimination of lipid peroxides by allene oxide synthase
JP2004505017A (en) Combination kit for the treatment of malaria containing chloroquine and 3- (1-(((4-((6-methoxy-8-quinolinyl) amino) pentyl) amino) -ethylidene) -dihydro-2 (3H) furanone
McCROSKEY et al. TRYPTIC DÉBRIDEMENT OF CLOTTED HEMOTHORAX: Experimental and Clinical Study
WO2022221988A1 (en) Pharmaceutical hydronidone formulations for diseases
US20120232041A1 (en) Pharmaceutical composition for treating or preventing angina or myocardial infarction induced by myocardial ischemia
Taneva Is Thrombolytic Therapy Effective in Elderly Patients? Bleeding?
DiMaggio et al. A Pain in the Back: A 50-Year-Old Man with Pancreatitis and a Fever
AU2022244386A1 (en) Prevention and treatment of coronavirus infection
AU2022267377A1 (en) Ketamine and cannabis for the treatment of emotional disorders
WO2013156955A1 (en) Diamine oxidase for use in the treatment or prevention of attention deficit hyperactivity disorder (adhd)
Asia et al. Rare Fungal Infection Emerges in Southwest
Mongan et al. Nerve and chemical agents

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION